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Abstract Recently, accumulating evidence has suggested
that tumors, including ovarian cancer, are composed of a
heterogeneous cell population with a small subset of cancer
stem cells (CSCs) that sustain tumor formation and growth.
The emergence of drug resistance is one of the most dif-
ﬁcult problems in the treatment of ovarian cancer, which
has been explained recently by the potential of CSCs to
have superior resistance against anti-cancer drugs than
conventional cancer cells. In this study, we expanded this
line of study to examine whether this phenomenon is also
observed in clinical specimens of ovarian cancer cells. In
total we could analyze 28 samples out of 60 obtained from
ovarian cancer patients. The clinical samples were sub-
jected to testing of the expression of side population (SP)
as a CSC marker, and according to the presence of SP
(SP?) or absence of SP (SP-), clinicopathological sig-
niﬁcances were analyzed. Although there was no statistical
signiﬁcance, there were more SP?s in recurrent cases as
well as in ascitic and peritoneal dissemination than in
primary tumor of the ovary. There was no correlation
between SP status and FIGO staging. In 19 cases of those
who could be followed more than 6 months from initial
therapy, there were 8 cases of recurrence or death from
disease, and all of these were SP?. On the other hand, in
11 cases of disease-free survivors, 6 were SP?. There was
a signiﬁcant difference in prognosis between SP? and SP-
(p = 0.017). Although this study was limited, it revealed
that SP could be contained more in recurrent or metastatic
tumors than in primary tumors, and also that the presence
of SP could be a risk factor of recurrence in ovarian cancer.
Therefore, a novel therapeutic strategy targeting SP could
improve the prognosis of ovarian cancer.
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Introduction
Ovarian cancer is the most lethal gynecological malig-
nancy. The number of ovarian cancer patients is gradually
increasing in Japan, as well as in the United States and
European countries. In 2008, 4,599 patients died of ovarian
cancer, making it the tenth most fatal malignancy in Japan.
Usually ovarian cancer patients lack symptoms because the
ovaries reside within the pelvic cavity, and effective
screening methods have not yet been developed. As a result,
more than half of the ovarian cancer patients are stage III or
IV at the time of diagnosis. Although taxanes improve 5-
year survival in advanced ovarian cancer [1], many patients
experience recurrence because of resistance to anti-cancer
drugs. Therefore, novel therapeutic strategies are needed.
Recently, accumulating evidence has suggested that
tumors, including ovarian cancer, are composed of a het-
erogeneous cell population with a small subset of cancer
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The emergence of drug resistance is one of the most dif-
ﬁcult problems in the treatment of ovarian cancer, but has
recently been explained by the discovery that CSCs have
resistance against anti-cancer drugs that is superior to that
of conventional cancer cells. Therefore, clarifying the
mechanism of CSC drug resistance could result in the
development of novel therapeutic strategies.
Several reports have shown that CSCs are enriched in a
side population (SP) that is recognized by ﬂuorescence-
activated cell sorting (FACS) [2–4]. To date, SP has been
detected in various solid tumor cells, such as breast [5],
colon [6, 7] and pancreatic cancer [8], as well as ovarian
cancer [9–11]. We also found that SP is signiﬁcantly
increased in chemoresistant ovarian cancer cell lines (in
submission). However, the signiﬁcance of SP in clinical
samples, such as cancer tissue or cancer cells in ascitic
ﬂuid, still remains unclear [12, 13]. Therefore, we con-
ducted a clinical study to clarify the signiﬁcance of SP in
clinical samples.
Materials and methods
Clinical samples
Clinical samples, such as cancer tissue or cancer cells in
ascitic ﬂuid, were obtained from patients with ovarian,
peritoneal or tubal cancer from January 2009 to July 2010 at
St. Marianna University Hospital. Informed consent was
obtained from all patients, and this study was approved by
theinternalreviewboardofourinstitution.Tissuesorascites
harvested during laparotomy or by ultrasound-guided
puncture were centrifuged to isolate the cellular component
and then resuspended in HAM-12 containing antibiotics.
Analysis of the side population in human ovarian
cancer tissues and ascites by ﬂow cytometry
Human ovarian cancer tissues were washed with phosphate-
buffered saline (PBS) and then cut into 1-mm-diameter
pieces. These pieces were then transferred into PBS con-
taining 2.4 U/ml of DISPASE
 (GIBCO) and incubated for
60 minat37C.AfterpassingthroughaCellStrainer
TMwith
70-lm pore size (BD Falcon), red blood cells were lysed
using PharmLyse
TM (BD Bioscience), and the resulting
single-cell suspension was diluted to 1.0 9 10
6 cells/ml.
For the staining of the SP, cells were pre-incubated for
10 min at 37C and then incubated for an additional 80 min
at 37C with 5 mg/ml Hoechst 33342 (Sigma-Aldrich,
Japan). SP cells were determined by the exclusion of Hoe-
chst 33342, which was inhibited by verapamil (Sigma-
Aldrich, Japan). Verapamil was added after pre-incubation
at the start of the Hoechst 33342 staining at a ﬁnal concen-
trationof50 lM.Livecellsweregatedbasedonforwardand
side scatter as well as lack of propidium iodide uptake. Flow
cytometry was performed using a J-SAN
 (Bay Bioscience,
Japan) instrument and analyzed by FlowJo
 software
(TOMY Digital Biology Co. Ltd., Japan). Tissues/cells that
satisﬁed the following conditions were deﬁned as tissues/
cells containing SP: (1) the percentage of cells in the SP
fractionwas[0.15%,and(2)afterverapamiladministration,
more than half of the cells were diminished from the SP
fraction. Mann-Whitney U test or Fisher’s exact probability
test were used to determine statistical signiﬁcance, and
p\0.05 was considered signiﬁcant.
Results
Clinical samples were obtained from a total of 60 patients.
Six cases were not primary ovarian cancer and were
excluded from this study. Among the remaining 54 sam-
ples, 26 could not be analyzed because they contained too
much debris, were contaminated with normal tissues or
were too small to be analyzed. In the 28 samples that were
evaluable for the study, the patient age ranged from 20 to
73 years old. Patient characteristics are shown in Table 1.
Of 28 samples, 18 contained an SP (SP?) and 10 did not
(SP-). Figure 1 shows the FACS analysis for a SP?
sample. The mean ages of SP? and SP- patients were 52.6
and 49.2 years old, respectively; however, they were not
signiﬁcantly different. Of 24 patients with samples
obtained at primary surgery or neoadjuvant chemotherapy
(NAC), 15 were SP? (62.5%). Of four recurrent cases,
three were SP? (75%). Although the difference between
primary and recurrent cases was not signiﬁcant (p = 0.55),
more recurrent cases were SP?.
Of 18 samples obtained directly from ovarian tumors, 10
were SP? (55.6%). However, of eight ascitic ﬂuid and two
peritonealdisseminationsamples,six(75%)andtwo(100%)
were SP?, respectively. Although the difference was not
signiﬁcant,thereweremoreSP?samplesinasciticﬂuidand
peritoneal dissemination than in primary ovarian tumors.
Focusing on the histology, there were eight cases of
endometrioid carcinoma (SP?: 5 vs. SP-: 3), seven cases
of serous carcinoma (4 vs. 3) and ﬁve cases of clear cell
carcinoma (3 vs. 2), with no correlation between SP? and
histology. According to FIGO staging, there were 11 cases
of stage I/II and 17 cases of stage III/IV. Of the stage I/II
cases, 5 were SP? (45.4%), while 13 of the stage III/IV
cases were SP? (76.5%). There was no correlation
between SP? and FIGO staging (p = 0.22).
In the 19 patients that could be followed more than
6 months from the initial therapy, there were 8 cases of
recurrent or fatal disease, and all 8 were SP?. However, in
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SP-.S P ? was signiﬁcantly correlated with a worse
prognosis than SP- (p = 0.017, Fig. 2). Of the SP? cases
that were histologically designated as serous and mucinous
carcinoma, all were recurrent or the patient died of disease.
Of the SP? clear cell carcinomas, two out of three cases
recurred or the patient died of disease. However, there was
no recurrent case in three SP? endometrioid carcinoma
cases.
Discussion
Several groups have reported about SP in ovarian cancer.
Szotek et al. detected SP in human ovarian cancer cell lines
Table 1 Patient characteristics that could be analyzed by FACS
Age Background Pathology FIGO Sample Prognosis
SP? group
37 0 Endometrioid Ic T
a
38 0 Endometrioid IIIa T DFS
38 0 LPM, serous Ic T
a
41 0 Endometrioid IIIc A
a
42 0 Serous IIIc T DOD
43 0 Clear IIIc T DOD
43 1 Clear IIIc A DOD
48 0 Serous IIIc T
a
48 0 Endometrioid Ic T DFS
56 0 Mucinous IIIc T AWD
56 0 Clear IIIc T DFS
60 0 Mucinous IIIc A DOD
61 1 Serous IIIc P AWD
62 0 Adenocarcinoma
b Ia A DFS
64 0 Serous IIIc P DOD
67 1 SSPC IIIc A DOD
69 0 Adenocarcinoma
c IIIc A
a
73 0 Endometrioid Ic T DFS
SP- group
20 0 Dysgerminoma Ia T
a
20 0 LPM, mucinous Ic A
a
40 1 Endometrioid IV T DFS
41 0 Endometrioid IIIc T
a
46 0 Endometrioid Ic T DFS
60 0 Clear Ic T DFS
61 0 Serous IIIc T DFS
67 0 Serous Ic T DFS
68 0 Serous IIIc A
a
69 0 Clear IIc T DFS
Background: 0: obtained from primary surgery; 1: recurrent case
Sample: T ovarian tumor, A ascites, P peritoneal dissemination
DFS disease-free survival, AWD alive with disease, DOD died of
disease
a Follow-up period\6 months
b Histological diagnosis could not be made due to chemotherapeutic
effect
c Laparotomy was not done, and histological diagnosis was made
only by cytology of ascitic ﬂuid
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Fig. 1 An example of a patient determined as SP? by ﬂow
cytometric analysis. After administration of verapamil, cells of the
SP fraction were diminished. Vertical axis intensity of Hoechst blue,
horizontal axis intensity of Hoechst red
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Fig. 2 Prognosis of the patients according to the presence or absence
of SP. *There was statistical signiﬁcance in the prognosis between
SP? and SP- (p = 0.017). Vertical axis number of cases. DFS
disease-free survival, AWD alive with disease, DOD died of disease
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in ovarian cancer were reported to have CSCs characteris-
tics, suggesting that CSCs are also enriched in SP in ovarian
cancer [9, 14]. In our clinical study, the presence of SP was
assessed in clinical tissues/cells in ovarian, peritoneal and
tubal carcinoma patients. A total of 54 cases were analyzed,
but the percentage of evaluable cases was only 51.9% (28/
54). The evaluable rate was relatively low because cancer
tissues in vivo could contain some amount of normal cells,
mucous and cell debris. Moreover, cancer tissues could
contain various polyclonal cancer cells. These factors might
have interfered with analysis by FACS in our study. For this
reason, novel procedures that could extract only cancer cells
from clinical samples should be developed.
Once ovarian cancer develops, the tumor surface rup-
tures, and tumor cells are disseminated into the peritoneal
cavity. Most ovarian cancers will spread by this process.
CSCs were reported to be related to metastasis [15–17],
which, if true, suggests that peritoneal dissemination could
be promoted by CSCs. In the present study, although it was
not statistically signiﬁcant, SP? cases were detected more
frequently in ascitic ﬂuid or peritoneal dissemination than
in primary tumors (75, 100 vs. 55.6%). This result suggests
that peritoneal dissemination in ovarian cancer is correlated
with SP, which is supported by the fact that SP? cases
were detected more frequently in FIGO stage III/IV
patients than in stage I/II (45.5 vs. 76.5%). Stage III/IV
patients already have peritoneal dissemination and/or dis-
tant metastasis, so it might be reasonable that SP could be
detected in tissues from stage III/IV patients.
Although the histological difference was not correlated
to the presence or absence of SP, in serous, mucinous and
clear cell carcinoma patients that were SP?, most experi-
enced recurrence or died of disease. However, SP?
endometrioid carcinoma patients did not experience
recurrence. Although the follow-up term was too short and
the number of patients too small to reach a conclusion, in
endometrioid carcinoma, the prognosis might not be
affected by the presence of SP.
In the present study, all eight SP? patients experienced
recurrence or died of disease within 2 years from initial
therapy, suggesting that SP might be correlated with the
risk of recurrence or death from disease. Some of these
patients were resistant to the initial chemotherapy, which
may indicate that SP containing rich CSCs is correlated to
chemoresistance. Therefore, although the number of the
studied cases was small, it indicates that detecting SP could
predict the chemoresistance or prognosis of ovarian cancer.
In conclusion, our study suggests that SP might be
correlated to peritoneal dissemination, and might also
predict chemoresistance or prognosis in ovarian cancer.
Because our study consisted of a small number of patients,
a larger study should be conducted in order to deﬁne the
clinical signiﬁcance of SP in ovarian cancer. The technical
difﬁculties of treating clinical samples for detecting SP/
CSCs should also be overcome.
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